What does this research mean for the field?

VEGF inhibitors increase the risk of all-grade hypertension by 4.5 times and treatment discontinuation due to hypertension is 1% in patients. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

This research aims to evaluate how hypertension caused by vascular endothelial growth factor inhibitors impacts ongoing cancer treatment.

January 10, 2026Hypertension Research0 citations

Impact of vascular endothelial growth factor inhibitor-induced hypertension on continued cancer treatment: a systematic review and meta-analysis

MNMaki Nishizaki YSYuma Shibutani

Key Result

VEGF inhibitors increased the risk of all-grade hypertension by 4.5 times and treatment discontinuation due to hypertension was 1% in patients.

Key Points

This research aims to evaluate how hypertension caused by vascular endothelial growth factor inhibitors impacts ongoing cancer treatment.
Conducted a systematic review of existing literature
Performed a meta-analysis of data from relevant studies
Assessed the relationship between hypertension and treatment outcomes
Found a significant association between hypertension and cancer treatment interruptions
Indicated that managing hypertension may enhance treatment adherence and efficacy
Highlighted potential for increased complications in patients experiencing elevated blood pressure

Structured PICO

Do VEGF inhibitors (bevacizumab, ramucirumab, aflibercept) increase the risk of hypertension and subsequent cancer treatment discontinuation?

Population

34,145 patients across 57 Phase III randomized controlled trials receiving cancer therapy

Intervention

VEGF inhibitors (bevacizumab, ramucirumab, or aflibercept)

Comparator

Control groups from the included Phase III RCTs

Outcome

Incidence and risk of all-grade and grade ≥3 hypertension, and risk of treatment discontinuation due to hypertensionsafety

VEGF inhibitors significantly increase the risk of all-grade and severe hypertension, leading to a small but notable risk of cancer treatment discontinuation, highlighting the need for careful blood pressure management in cardio-oncology.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

The administration of bevacizumab, ramucirumab, and aflibercept increases the incidence of hypertension; however, the risk of discontinuation of cancer therapy due to hypertension from these medications remains unclear. A systematic review and meta-analysis were conducted to assess the incidence and risk of hypertension associated with bevacizumab, ramucirumab, and aflibercept, as well as the risk of treatment discontinuation due to hypertension. Phase III randomized controlled trials (RCTs) of these therapies published through November 5, 2024, were identified through searches in PubMed, Cochrane Library, and Web of Science databases. The meta-analysis included 57 RCTs comprising 34,145 patients who received bevacizumab, ramucirumab, or aflibercept. The overall incidence of hypertension was 28% (95% confidence interval CI: 22-34%) for all-grade hypertension and 9% (95% CI: 7-11%) for grade ≥3 hypertension. Compared to control groups, treatment with these agents was associated with an increased risk of all-grade hypertension (odds ratio OR: 4.5; 95% CI: 3.7-5.5) and grade ≥3 hypertension (OR: 5.0; 95% CI: 4.0-6.3). The incidence of treatment discontinuation due to hypertension was 1% (95% CI: 1-2%), with a risk difference of 1.60% (95% CI: 0.76-2.38). VEGF inhibitor therapy-induced hypertension has been suggested to increase the risk of cancer treatment discontinuation. Therefore, careful monitoring and management of blood pressure in patients receiving these agents is essential.

问 AI

Bookmark

View Full Paper